中山醫學大學機構典藏 CSMUIR:Item 310902500/15737
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 17935/22950 (78%)
造訪人次 : 7500279      線上人數 : 667
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋


    請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/15737


    題名: The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies.
    作者: SC, Su
    CW, Lin
    WE, Yang
    WL, Fan
    SF, Yang
    貢獻者: 中山醫大口腔科學研究所
    關鍵詞: Angiogenesis;extracellular matrix (ECM);integrin;malignancy;matrix metalloprotease (MMP);metastasis;urokinase plasminogen activator (uPA)
    日期: 2015-12-14
    上傳時間: 2016-08-11T04:09:00Z (UTC)
    ISSN: 1472-8222
    摘要: INTRODUCTION:

    The urokinase plasminogen activator (uPA) system, comprising the serine protease uPA, its cognate receptor, uPAR, and two endogenous inhibitors, plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2), is a key player in the break-down of extracellular matrix (ECM) and basement membrane. Elevated expression of uPA and uPAR is observed in numerous cancer types and associated with poor prognosis.

    AREAS COVERED:

    In addition to the aberrant expression during tumor development, the components of uPA system are functionally involved in various processes that are prerequisite for cancer progression. These processes include, but not limited to, ECM degradation, angiogenesis, cell proliferation, adhesion, migration and epithelial-mesenchymal transition. All of these findings implicate uPA system as a target for cancer treatment. Thus, therapeutic agents and approaches to targeting the constituents of uPA system, mainly at their expression level and biological activities, have been extensively used in antineoplastic investigations.

    EXPERT OPINION:

    Because of promising results obtained from previous preclinical studies, several clinical trials aimed at inhibiting the expression or function of uPA/uPAR have been completed or are ongoing. In these trials, favorable outcomes in reducing metastatic spread and extending the lifespan of cancer patients have been reported, and no severe adverse events were observed.
    URI: http://dx.doi.org/10.1517/14728222.2016.1113260
    https://ir.csmu.edu.tw:8080/ir/handle/310902500/15737
    關聯: Expert Opin Ther Targets. 2016 May;20(5):551-66.
    顯示於類別:[牙醫學系暨碩士班] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML369檢視/開啟


    檢視Licence

    SFX Query

    在CSMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋